MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

uniQure NV Company Profile (NASDAQ:QURE)

Consensus Ratings for uniQure NV (NASDAQ:QURE) (?)
Ratings Breakdown: 10 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.11 (315.95% upside)

Analysts' Ratings History for uniQure NV (NASDAQ:QURE)
Show:
DateFirmActionRatingPrice TargetActions
6/30/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016WallachBeth CapitalLower Price TargetBuy$60.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/12/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2016Chardan CapitalReiterated RatingBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2016HC WainwrightReiterated RatingBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/8/2016Janney Montgomery ScottReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/8/2016Roth CapitalReiterated RatingBuy$37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2015BMO Capital MarketsReiterated RatingOutperform -> PositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for uniQure NV (NASDAQ:QURE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/25/2016        
5/31/2016Q1($0.82)($0.93)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/4/2016Q415($0.60)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/30/2015Q315($0.64)($1.14)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/27/2015Q215($0.56)($0.98)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
6/11/2015Q1($0.82)($0.69)$9.50 million$1.17 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/6/2015($0.62)($0.77)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/1/2014($0.53)($0.61)$2.00 million$1.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/2/2014Q214($0.55)($1.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
6/6/2014($0.45)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for uniQure NV (NASDAQ:QURE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.94)($0.63)($0.75)
Q2 20163($0.98)($0.74)($0.85)
Q3 20163($1.00)($0.77)($0.87)
Q4 20163($1.03)($0.80)($0.90)
(Data provided by Zacks Investment Research)
Dividend History for uniQure NV (NASDAQ:QURE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for uniQure NV (NASDAQ:QURE)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for uniQure NV (NASDAQ:QURE)
DateHeadline
06/30/16 08:51 AMProtein Sciences Announces Exclusive License to uniQure of Cell Line and Technology for Production of Human Gene ... - PR Newswire (press release)
06/30/16 08:51 AMCovering the Bases on uniQure N.V. (NASDAQ:QURE): Where is the Stock Going? - Press Telegraph
06/28/16 05:56 PMDiscover the amyotrophic lateral sclerosis pipeline landscape and therapeutics under development market review 2016
06/28/16 10:52 AMProtein Sciences Announces Exclusive License to uniQure of Cell Line and Technology for Production of Human Gene Therapies
06/27/16 05:59 PMuniQure Appoints Maria E. Cantor as Senior Vice President, Investor Relations & Communications - GlobeNewswire (press release)
06/27/16 05:59 PMuniQure Appoints Maria E. Cantor as Senior Vice President, Investor Relations Communications - EconoTimes
06/24/16 08:39 AMBiotechnology Decliners: uniQure N.V. (NASDAQ:QURE), ImmunoGen, Inc. (NASDAQ:IMGN), Alexion Pharmaceuticals ... - KC Register
06/24/16 08:39 AMuniQure N.V. (NASDAQ:QURE) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 08:39 AMCould Uniqure NV See a Reversal After This Very Weak Session? - Press Telegraph
06/24/16 08:39 AMUniqure NV Ord (NASDAQ:QURE) Sellers Covered 4.69% of Their Shorts - Press Telegraph
06/21/16 10:23 AMTrader's Watch List: uniQure N.V. (NASDAQ:QURE), Bon-Ton Stores Inc. (NASDAQ:BONT), Rite Aid (NYSE:RAD ... - KC Register
06/17/16 05:49 PMNew Data Spark Hemophilia B Gene Therapy Battle - Seeking Alpha
06/15/16 05:57 PMUniqure NV 271.2% Potential Upside Now Implied by WallachBeth - DirectorsTalk Interviews
06/12/16 10:55 PM11:55 pm uniQure reports Phase I/II clinical data demonstrating 6 months of sustained increases in Factor IX activity -
06/11/16 08:56 AMuniQure NV: uniQure Presents Clinical Data from Ongoing Phase I/II Study in Hemophilia B Demonstrating 6 Months of ... - The Wall Street Transcript
06/11/16 04:49 AMuniQure Presents Clinical Data from Ongoing Phase I/II Study in Hemophilia B Demonstrating 6 Months of Sustained Increases in Factor IX Activity - [at noodls] - --Data from Low-Dose Cohort Presented at the 21st Congress of the European Hematology Association Show Durable and Therapeutically Relevant Factor IX (FIX) Expression-- --Median FIX Activity for All Five ...
06/10/16 09:03 AMTrend Of Rating Given To uniQure N.V. (NASDAQ:QURE) - Investor Newswire
06/08/16 06:32 PMUNIQURE NV (NASDAQ:QURE) Financial Condition Compared to S&P 500 - CML News
06/08/16 09:04 AMAMN Healthcare Services Inc. (NYSE:AHS) increased 3.06%: uniQure N.V. (NASDAQ:QURE), Rent-A-Center, Inc ... - KC Register
06/07/16 10:12 AMuniQure NV :QURE-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016 -
06/07/16 08:48 AMRevenue Update on Uniqure NV(NASDAQ:QURE) - Trade Calls
06/05/16 08:43 AMAre Analysts Bearish Uniqure NV (NASDAQ:QURE) After Last Week? - HNN
06/04/16 06:04 PMUniqure NV (QURE) Stock Rating Reaffirmed by Oppenheimer - Let Me Know About This
06/04/16 08:58 AMUniqure NV (QURE) Earns “Buy” Rating from Jefferies Group - Let Me Know About This
06/03/16 06:37 PMEquities Analysts Set Expectations for Uniqure NV's Q2 2016 Earnings (QURE) - Let Me Know About This
06/02/16 06:29 PMuniQure N.V. (NASDAQ:QURE) Stock Update & Estimates - Stock Tick Tock - uniQure N.V. (NASDAQ:QURE) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting uniQure N.V. (NASDAQ:QURE) to post earnings of $-0.83 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...and more »
06/02/16 09:02 AMUniqure NV (QURE) Receives “Buy” Rating from Cowen and Company - Let Me Know About This - Uniqure NV (QURE) Receives “Buy” Rating from Cowen and CompanyLet Me Know About ThisUniqure NV logo Uniqure NV (NASDAQ:QURE)'s stock had its “buy” rating reissued by analysts at Cowen and Company in a report issued on Thursday. QURE has been the subject of a number of other reports. Chardan Capital reissued a “buy” rating and ...Cowen and Company Reiterates Buy Rating for Uniqure NV (QURE)The Cerbat GemUniqure BV (NASDAQ:QURE) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsuniQure NV (NASDAQ:QURE) Stock Update & EstimatesStock Tick Tockall 4 news articles »
06/01/16 08:58 AMHot Stock to Track: Uniqure NV (NASDAQ:QURE) - The Point Review - Hot Stock to Track: Uniqure NV (NASDAQ:QURE)The Point ReviewUniqure NV (NASDAQ:QURE) has a market cap of $329.40 million and the number of outstanding shares have been calculated to be 24.33 million shares. One more important factor to consider when evaluating a stock's current and future value are the 52 ...Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), uniQure N.V. (NASDAQ: QURE), Amarin ...Analyst Ratingsall 2 news articles »
05/31/16 06:22 PMUniqure NV (QURE) Releases Earnings Results, Misses Estimates By $0.10 EPS - Let Me Know About This - Uniqure NV (QURE) Releases Earnings Results, Misses Estimates By $0.10 EPSLet Me Know About ThisUniqure NV logo Uniqure NV (NASDAQ:QURE) issued its earnings results on Tuesday. The company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.82) by $0.10. Shares of Uniqure NV ...
05/31/16 06:22 PMCompany Update (NASDAQ:QURE): Uniqure NV Announces Results for First Quarter 2016 - Smarter Analyst - Company Update (NASDAQ:QURE): Uniqure NV Announces Results for First Quarter 2016Smarter AnalystUniqure NV (NASDAQ:QURE), a leader in human gene therapy, announced financial results for the first quarter ending March 31, 2016, and provided a corporate update. “We are very pleased with our progress so far in 2016 as we continue to advance our ...uniQure Q1 Loss Misses Street Mark, Beats on Revenues (NASDAQ:QURE)Sonoran Weekly ReviewBroker Outlook For The Week Ahead: Uniqure BV (NASDAQ:QURE)Share Trading Newsall 3 news articles »
05/31/16 08:06 AMBroker Outlook For The Week Ahead: Uniqure BV (NASDAQ:QURE) - Share Trading News - Broker Outlook For The Week Ahead: Uniqure BV (NASDAQ:QURE)Share Trading NewsUniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a ...
05/31/16 08:06 AMuniQure NV: uniQure Announces Results for First Quarter 2016 - The Wall Street Transcript - uniQure NV: uniQure Announces Results for First Quarter 2016The Wall Street Transcript'We are very pleased with our progress so far in 2016 as we continue to advance our clinical and preclinical programs and build out our gene therapy platform,' commented Daniel Soland, Chief Executive Officer of uniQure. 'We achieved two important ...uniQure Q1 Loss Misses Street Mark, Beats on Revenues (NASDAQ:QURE)Sonoran Weekly Reviewall 3 news articles »
05/31/16 06:07 AMQ1 2016 Uniqure NV Earnings Release - Time Not Supplied -
05/31/16 04:35 AMUniQure reports 1Q loss -
05/26/16 12:44 PMUniqure NV Ord (NASDAQ:QURE) Sellers Covered 6.2% of Their Shorts - Wall Street Hints and News - Uniqure NV Ord (NASDAQ:QURE) Sellers Covered 6.2% of Their ShortsWall Street Hints and NewsThe stock of Uniqure NV Ord (NASDAQ:QURE) registered a decrease of 6.2% in short interest. QURE's total short interest was 1.30M shares in May as published by FINRA. Its down 6.2% from 1.38 million shares, reported previously. With 186,100 shares ...and more »
05/21/16 01:26 PMSpark Surges After Gene Therapy Helps 3 Hemophilia Patients - All the patients had severe hemophilia and needed regular infusions prior to joining the trial, said George. UniQure NV, the Dutch biotechnology company that developed the first gene therapy approved in Europe, is also working on a treatment for hemophilia ...
05/20/16 01:51 PMuniQure N.V. (NASDAQ:QURE) One-Year Price Projection At $35.333 - Investor Newswire - uniQure N.V. (NASDAQ:QURE) One-Year Price Projection At $35.333Investor NewswireSell-side analysts are certain on the prospect of uniQure N.V. (NASDAQ:QURE) stock. As of 2016-05-18, the stock ABR stands at 1. This type of rating states that whenever a stock has a score of 5, investors should avoid investing in such stocks ...and more »
05/19/16 01:26 PMBuy Calls Count For uniQure N.V. (NASDAQ:QURE) At 0 - Investor Newswire - Buy Calls Count For uniQure N.V. (NASDAQ:QURE) At 0Investor NewswireBuy calls count is 0 and Sell recommendations is 0 while hold recommendations is 0. uniQure N.V. (NASDAQ:QURE) has a total of 9 Strong Buy recommendations and 0 Strong Sell calls as of 2016-05-16. One month ago, the count of strong buy ratings were ...and more »
05/19/16 01:26 PMuniQure NV: uniQure Announces Oral Presentation of Clinical Data from Ongoing Phase I/II Study of AMT-060 in ... - The Wall Street Transcript - uniQure NV: uniQure Announces Oral Presentation of Clinical Data from Ongoing Phase I/II Study of AMT-060 in ...The Wall Street TranscriptAmsterdam, the Netherlands,May 19, 2016 - uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that additional data from its Phase I/II trial of AMT-060 in hemophilia B will be presented on June 11, 2016 at the 21 Congress of ...and more »
05/19/16 05:52 AMuniQure Announces Oral Presentation of Clinical Data from Ongoing Phase I/II Study of AMT-060 in Hemophilia B at the 21st Congress of the European Hematology Association - [at noodls] - - Presentation to Include Most Recent Clinical Data from the Five Patient, Low-dose Cohort - - Company to Host Conference Call on Monday, June 13, 2016 at 2:00 pm CET/ 8:00 am EDT - Amsterdam, the Netherlands,May ...
05/13/16 08:09 AMuniQure N.V. (NASDAQ:QURE) One-Year Mean Price Target At $34.571 - Investor Newswire - uniQure N.V. (NASDAQ:QURE) One-Year Mean Price Target At $34.571Investor NewswireSell-side analysts are confident on the future outlook of uniQure N.V. (NASDAQ:QURE) stock. As of 2016-05-11, the stock has an ABR of 1 rating, where number 5 denotes a Strong Sell and 1 Strong Buy. The ABR is reached on the basis of estimates of 7 ...and more »
05/12/16 08:23 AMPerformance Recap and Target Perspective on uniQure N.V. (NASDAQ:QURE) - B.O.D.Y Confidential - Performance Recap and Target Perspective on uniQure N.V. (NASDAQ:QURE)B.O.D.Y ConfidentialIn the latest trading session, shares of uniQure N.V. (NASDAQ:QURE) moved -4.7481%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a recent check, company shares ...and more »
05/12/16 04:27 AMuniQure to Present at Upcoming Investor Conferences in New York City - [at noodls] - Amsterdam, the Netherlands, May 12, 2016 - uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that its management will be presenting at the below listed investor conferences in ...
05/11/16 07:24 AMUniQure secures $20M in new loan capacity from Hercules - Seeking Alpha - UniQure secures $20M in new loan capacity from HerculesSeeking AlphaUniQure (NASDAQ:QURE) updates its loan agreement with Hercules Technology Growth Capital, increasing the total commitment to $40M, $20M which is currently outstanding. The facility isn't cheap, though. The interest rate is 8.25% per annum, but there is ...How Analysts Feel About Uniqure NV (NASDAQ:QURE)?The Postall 2 news articles »
05/10/16 07:58 AMBRIEF-Uniqure NV intends to transition to a single board of directors - Reuters - BRIEF-Uniqure NV intends to transition to a single board of directorsReutersMay 9 Uniqure NV. * Intends to transition from current two-tier supervisory board and management board structure to a single board of directors. * Announced nomination of Jack Kaye to stand for election to uniqure's board of directors. * Will propose ...
05/10/16 07:58 AMForm 6-K uniQure NV For: May 09 - StreetInsider.com - Form 6-K uniQure NV For: May 09StreetInsider.comAmsterdam, the Netherlands, May 9, 2016 — uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the data from several preclinical research programs focused on the development and validation of new technologies to improve ...uniQure Gains 2% – Unveils Significant Preclinical Data on Gene Therapy Technology (NASDAQ:QURE)Sonoran Weekly Reviewall 3 news articles »
05/09/16 03:24 PMuniQure Announces the Nomination of Jack Kaye to its Board of Directors and Proposed Corporate Governance Changes - [GlobeNewswire] - AMSTERDAM, The Netherlands -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the nomination of Jack Kaye to stand for election to uniQure's Board of Directors. Mr. Kaye, who ...
05/09/16 07:43 AMuniQure Presents Preclinical Data on AAV Re-Administration, Regulated Gene Expression and Total Brain ... - GlobeNewswire (press release) - uniQure Presents Preclinical Data on AAV Re-Administration, Regulated Gene Expression and Total Brain ...GlobeNewswire (press release)AMSTERDAM, the Netherlands, May 9, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the data from several preclinical research programs focused on the development and validation of new ...and more »
05/09/16 07:43 AMAfter Last Week What Do Analysts Think Of Uniqure BV (NASDAQ:QURE) - Share Trading News - After Last Week What Do Analysts Think Of Uniqure BV (NASDAQ:QURE)Share Trading News05/06/2015 – Uniqure BV had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 49 price target on the stock. 03/03/2014 – Raymond James began new coverage on Uniqure BV giving the company a “market perform” ...
05/09/16 04:16 AMuniQure Presents Preclinical Data on AAV Re-Administration, Regulated Gene Expression and Total Brain Transduction at ASGCT - [at noodls] - Amsterdam, the Netherlands, May 9, 2016 - uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the data from several preclinical research programs focused on the development and ...
About uniQure NV

uniQure NV logoUniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. The Company's first product is Glybera, for the treatment of lipoprotein lipase deficiency (LPLD). In the clinical pipeline, it has gene treatments for hemophilia, porphyria, Parkinson, Sanfilippo B syndrome and hearing loss. Additionally, it is engaged in the development of therapies based on adeno-associated virus (AAV) through multiple collaborations. The Company uses modular technology platform, including a cost effective manufacturing process. In August 2014, Uniqure NV acquired InoCard GmbH, an early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: QURE
  • CUSIP:
Key Metrics:
  • Previous Close: $7.72
  • 50 Day Moving Average: $10.89
  • 200 Day Moving Average: $13.63
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $191.60M
  • Current Quarter EPS Consensus Estimate: $-3.19 EPS
Additional Links:
uniQure NV (NASDAQ:QURE) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha